Trial Search Results

Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes

The term epidermolysis bullosa (EB) is used to describe a group of genetic skin diseases associated with skin weakness, blisters, and chronic wounds. "Revertant mosaicism" means that there are two genetically different populations of cells due to spontaneous mutations. Some EB patients have normal, non-fragile skin patches which may be areas of revertant mosaicism. In the revertant areas, the proteins function normally, like non-EB skin. In this study, we plan to culture cells from the revertant areas and graft them on to the wounded areas.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Procedure: Grafting of Autologous Cultured Revertant Keratinocytes




Inclusion Criteria:

   - Clinical diagnosis of EB (simplex, junctional or dystrophic)

   - Areas of revertant skin that has been confirmed by biopsy

   - 18 years or older subject willing and able to give consent

   - Confirmation of EB diagnosis by immunofluorescence (IF), electron microscopy (EM), and
   genetic testing confirming mutation

   - At least 100 to 200 cm2 of open erosions on the trunk and/or extremities suitable for
   skin grafting

   - Able to undergo adequate anesthesia to allow grafting procedures to take place

Exclusion Criteria:

   - Medical instability limiting ability to travel to Stanford University Medical Center

   - The presence of medical illness expected to complicate participation and/or compromise
   the safety of this technique

   - Active infection with HIV, hepatitis B, or hepatitis C

   - Active infection in the area that will undergo grafting

   - Evidence of a systemic infection

   - Current evidence or a history of skin cancer in the area that will undergo grafting

   - Active drug or alcohol addiction

   - Hypersensitivity to vancomycin or amikacin

   - Receipt of chemical or biological study product for the specific treatment ofEB in the
   past six months

   - Positive pregnancy test or breast-feeding

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Emily S Gorell, MS
Not Recruiting